Identification

Name
Nadroparin
Accession Number
DB08813
Type
Small Molecule
Groups
Approved, Investigational
Description

Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Nadroparin calciumLIA7Z4002P37270-89-6Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1998-02-05Not applicableCanada
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1998-02-05Not applicableCanada
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1998-02-05Not applicableCanada
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1998-02-05Not applicableCanada
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1998-02-05Not applicableCanada
Fraxiparine ForteSolution19000 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1999-06-22Not applicableCanada
Fraxiparine ForteSolution19000 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1999-06-22Not applicableCanada
Fraxiparine ForteSolution19000 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1999-06-22Not applicableCanada
Categories
UNII
1K5KDI46KZ
CAS number
9041-08-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction

Associated Conditions
Pharmacodynamics

Nadroparin is a low molecular weight heparin that is composed of a heterogeneous mixture of sulfated polysaccaride glycosaminoglycan chains. Th mean molecular weight is approximately 4300 daltons. The ratio of anti-Xa activity to anti-IIa is 3.5:1 whereas it is about 1:1 for heparin. Its use should be avoided in patients with a creatinine clearance less than 40mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.

Mechanism of action

The mechanism of action for nadroparin is similar to all other LMWHs. Like all LMWHs, nadroparin has a pentasaccharide sequence which binds to ATIII, which potentiates the action of ATIII. This complex greatly accelerates the inactivation of factor Xa and factor IIa. As a result, the coagulation cascade is inhibited.

TargetActionsOrganism
AAntithrombin-III
potentiator
Human
UP-selectin
inhibitor
Human
UProto-oncogene c-Fos
inhibitor
Human
UMyc proto-oncogene protein
inhibitor
Human
Absorption

Absorption is linear. The bioavailability of nadroparin after subcutaneous administration is about 89%.

Volume of distribution

3.59L

Protein binding

Much lower compared to heparin, which has over 90% protein bound.

Metabolism

Nadroparin is metabolized in the liver.

Route of elimination

Nadroparin is eliminated via the kidneys through non-saturable mechanisms.

Half life

In healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.

Clearance

The clearance of nadroparin is 21.4 +/- 7.0mL/min

Toxicity

Osteopenia with extended use, skin necrosis, thrombocytosis, severe immunologically-mediated thrombocytopenia, eosinophilia (rare), calcinosis rarely occurs at the injection site, severe bleeding, transient elevation of liver transaminases.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Nadroparin.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Nadroparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Nadroparin.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Nadroparin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Nadroparin.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
AliskirenNadroparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Nadroparin.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Nadroparin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Nadroparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Nadroparin.Approved
AltrenogestThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Altrenogest.Vet Approved
AmilorideNadroparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Nadroparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Nadroparin.Approved
AncrodAncrod may increase the anticoagulant activities of Nadroparin.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Nadroparin.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Nadroparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Nadroparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Antithrombin III humanNadroparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Nadroparin.Approved
ApocyninApocynin may increase the anticoagulant activities of Nadroparin.Investigational
ApremilastApremilast may increase the anticoagulant activities of Nadroparin.Approved, Investigational
AprotininThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Nadroparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Nadroparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Nadroparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Nadroparin.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Nadroparin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilNadroparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Nadroparin.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Nadroparin.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Nadroparin.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Nadroparin.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Nadroparin.Approved
BeraprostBeraprost may increase the anticoagulant activities of Nadroparin.Investigational
BevoniumBevonium may increase the anticoagulant activities of Nadroparin.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Nadroparin.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Nadroparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Nadroparin.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Nadroparin.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Nadroparin.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Nadroparin.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Nadroparin.Investigational
CanagliflozinNadroparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanNadroparin may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilNadroparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CangrelorCangrelor may increase the anticoagulant activities of Nadroparin.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Nadroparin.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Nadroparin.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Nadroparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
CertoparinNadroparin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlormadinoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Chlormadinone.Experimental
ChloroquineChloroquine may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Nadroparin.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Nadroparin.Approved
CilostazolCilostazol may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Citric AcidCitric Acid may increase the anticoagulant activities of Nadroparin.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Nadroparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Nadroparin.Approved
CloricromenCloricromen may increase the anticoagulant activities of Nadroparin.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Nadroparin.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Nadroparin is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Nadroparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Nadroparin.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Nadroparin.Experimental
DalteparinDalteparin may increase the anticoagulant activities of Nadroparin.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
DarexabanNadroparin may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
DemegestoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Demegestone.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Nadroparin.Investigational
DesirudinNadroparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Nadroparin.Investigational
DesogestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Desogestrel.Approved
DextranNadroparin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Nadroparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
DienogestThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Nadroparin.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Nadroparin.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Nadroparin.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Nadroparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Nadroparin.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Nadroparin.Investigational
DydrogesteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Nadroparin.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Nadroparin.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Nadroparin.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Nadroparin.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Nadroparin.Approved
EplerenoneNadroparin may increase the hyperkalemic activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Nadroparin.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Nadroparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Nadroparin.Approved
EprosartanNadroparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Nadroparin.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Nadroparin.Approved
EstroneEstrone may decrease the anticoagulant activities of Nadroparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Nadroparin.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Nadroparin.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Nadroparin.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Nadroparin.Withdrawn
EthynodiolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Nadroparin.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Nadroparin.Investigational, Nutraceutical
ExisulindExisulind may increase the anticoagulant activities of Nadroparin.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Nadroparin.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Nadroparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Nadroparin.Approved
FentiazacFentiazac may increase the anticoagulant activities of Nadroparin.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Nadroparin.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Nadroparin.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Nadroparin.Investigational
FimasartanNadroparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
FluindioneNadroparin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Nadroparin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Nadroparin.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
FondaparinuxNadroparin may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Nadroparin.Approved, Investigational
ForasartanNadroparin may increase the hyperkalemic activities of Forasartan.Experimental
GabexateNadroparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Nadroparin.Investigational
GestodeneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Nadroparin.Experimental
HeminHemin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Nadroparin.Experimental
HeparinHeparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Nadroparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Nadroparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Nadroparin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nadroparin is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nadroparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Nadroparin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Nadroparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Nadroparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Nadroparin.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Nadroparin.Investigational
IloprostIloprost may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Nadroparin.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Nadroparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Nadroparin.Withdrawn
IrbesartanNadroparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Nadroparin.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Nadroparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Nadroparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Nadroparin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
LepirudinNadroparin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanNadroparin may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Nadroparin.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Nadroparin.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Nadroparin.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Nadroparin.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Nadroparin.Approved, Investigational
LosartanNadroparin may increase the hyperkalemic activities of Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
LynestrenolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Lynestrenol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Nadroparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Nadroparin.Approved
Megestrol acetateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranNadroparin may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Nadroparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Nadroparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Nadroparin.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Nadroparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Nadroparin.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Nadroparin.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Nadroparin.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Nadroparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Nadroparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Nadroparin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Nadroparin.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Nadroparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Nadroparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Nadroparin.Investigational
NomegestrolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Nadroparin is combined with Obinutuzumab.Approved, Investigational
OlmesartanNadroparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Nadroparin.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Nadroparin.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Nadroparin is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Nadroparin.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Nadroparin can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Nadroparin.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Nadroparin.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Nadroparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Nadroparin.Investigational
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Nadroparin.Approved
PalmidrolPalmidrol may increase the anticoagulant activities of Nadroparin.Experimental, Nutraceutical
ParecoxibParecoxib may increase the anticoagulant activities of Nadroparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Nadroparin.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Nadroparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Nadroparin.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Nadroparin.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Nadroparin.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Nadroparin.Approved
Potassium CitrateNadroparin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Nadroparin.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Nadroparin.Approved
ProgesteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Nadroparin.Experimental
PromegestoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Nadroparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Nadroparin.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Nadroparin.Experimental
Protein CNadroparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanNadroparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNadroparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Nadroparin.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Nadroparin.Approved
QuingestanolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Quingestanol.Experimental
RamatrobanRamatroban may increase the anticoagulant activities of Nadroparin.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Nadroparin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Nadroparin.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Nadroparin.Approved, Investigational
ReviparinNadroparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Nadroparin.Approved
RivaroxabanNadroparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Nadroparin.Approved, Investigational
SacubitrilNadroparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Nadroparin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Nadroparin.Approved
SaprisartanNadroparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinNadroparin may increase the hyperkalemic activities of Saralasin.Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Nadroparin.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Nadroparin.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Nadroparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Nadroparin.Approved
SemapimodSemapimod may increase the anticoagulant activities of Nadroparin.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Nadroparin.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Nadroparin.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
Sodium CitrateNadroparin may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SpironolactoneNadroparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Nadroparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Nadroparin.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Nadroparin.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Nadroparin.Approved
SulindacSulindac may increase the anticoagulant activities of Nadroparin.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Nadroparin.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Nadroparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nadroparin.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Nadroparin.Investigational
TasosartanNadroparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanNadroparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Nadroparin.Approved
TenidapTenidap may increase the anticoagulant activities of Nadroparin.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Nadroparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Nadroparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Nadroparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Nadroparin.Investigational
Testosterone cypionateThe therapeutic efficacy of Nadroparin can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Nadroparin can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Nadroparin can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Nadroparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Nadroparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Nadroparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Nadroparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Nadroparin.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Nadroparin.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Nadroparin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Nadroparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Nadroparin is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Nadroparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TriamtereneNadroparin may increase the hyperkalemic activities of Triamterene.Approved
TribenosideTribenoside may increase the anticoagulant activities of Nadroparin.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Nadroparin.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Nadroparin.Approved
TroxerutinNadroparin may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
ValsartanNadroparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Nadroparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Nadroparin.Approved
WarfarinWarfarin may increase the anticoagulant activities of Nadroparin.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Nadroparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Nadroparin.Withdrawn
Food Interactions
  • Danshen, dong quai, evening primrose oil, gingko, policosanol, willowbark

References

General References
  1. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thebault JJ: Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995 Apr;73(4):630-40. [PubMed:7495071]
  2. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165]
  3. Lai KN, Wang AY, Ho K, Szeto CC, Li M, Wong LK, Yu AW: Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis. 1996 Nov;28(5):721-6. [PubMed:9158210]
  4. Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sie P: Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. Thromb Haemost. 1998 Feb;79(2):338-41. [PubMed:9493587]
  5. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H: Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci. 1999 May;8(2):119-25. [PubMed:10210734]
  6. Ng HJ, Lee LH: Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy. Int J Hematol. 2003 Feb;77(2):185-7. [PubMed:12627856]
  7. Breddin HK: Prophylaxis and treatment of deep-vein thrombosis. Semin Thromb Hemost. 2000;26 Suppl 1:47-52. [PubMed:11011806]
  8. Haas SK: Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost. 2002 Dec;28(6):577-84. [PubMed:12536351]
  9. Davis R, Faulds D: Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997 Apr;10(4):299-322. [PubMed:9108990]
  10. Iaremchuk AIa, Zotov AS, Cheshuk VE, Anikuc'ko NF, Zakhartseva LM, Diatel MV, Kravchenko AV, Lobanova OE, Sidorchuk OI: [Clinical effectiveness of nadroparin calcium in the surgical treatment of breast cancer]. Vopr Onkol. 2003;49(2):205-8. [PubMed:12785206]
  11. Vitale FV, Rotondo S, Sessa E, Antonelli G, Colina P, Parisi A, Giamo V, Ferrau F: Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases. J Oncol Pharm Pract. 2011 Jun;17(2):141-4. doi: 10.1177/1078155209353465. Epub 2009 Dec 16. [PubMed:20015933]
  12. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009 Oct;10(10):943-9. doi: 10.1016/S1470-2045(09)70232-3. Epub 2009 Aug 31. [PubMed:19726226]
External Links
PubChem Substance
347910374
Wikipedia
Nadroparin
ATC Codes
B01AB06 — Nadroparin
AHFS Codes
  • 20:12.04.16 — Heparins

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3CompletedTreatmentHepatocellular,Carcinoma1
2, 3Unknown StatusPreventionDeep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)1
3CompletedPreventionCancer, Advanced / Metastatic Cancers1
3CompletedPreventionThrombosis, Venous1
3CompletedPreventionVenous Thromboembolism1
3CompletedTreatmentThrombosis, Venous1
3TerminatedTreatmentNeoplasms / Venous Thromboembolism1
3Unknown StatusPreventionPregnancy and Thrombophilia1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Liver Cirrhosis / Status;Splenectomy / Thrombosis, Venous1
4CompletedTreatmentKidney Failures, Acute1
4CompletedTreatmentPulmonary Embolism (PE) / Thromboembolism / Thrombosis / Vascular Diseases1
4Not Yet RecruitingTreatmentLiver Cirrhosis / Portal Vein Thrombosis1
4RecruitingPreventionDeep Venous Thrombosis / Pulmonary Embolism (PE)1
4RecruitingPreventionHigh Blood Pressure (Hypertension) / Liver Cirrhosis / Status;Splenectomy / Thrombosis, Venous1
4RecruitingTreatmentEndstage Renal Disease1
4RecruitingTreatmentLiver Cirrhosis / Portal Vein Thrombosis1
4TerminatedNot AvailableCancers / Venous Thromboembolism1
4Unknown StatusPreventionBypass Complications / Obesity, Morbid / Thromboembolism1
4Unknown StatusTreatmentAcute Ischemic Stroke (AIS)1
4Unknown StatusTreatmentPulmonary Embolism (PE) / Pulmonary Thromboembolisms1
Not AvailableCompletedNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableCompletedPreventionNeoplasms, Esophageal / Neoplasms, Lung / Venous Thromboembolism1
Not AvailableRecruitingPreventionDeep-Venous Thrombosis1
Not AvailableUnknown StatusBasic ScienceHemodialysis-dependent patients / Renal Failure1
Not AvailableWithdrawnTreatmentAnticoagulation / Liver Cirrhosis / Portal Vein Thrombosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntravenous; Subcutaneous9500 unit
SolutionIntravenous; Subcutaneous19000 unit
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
Gene Name
SERPINC1
Uniprot ID
P01008
Uniprot Name
Antithrombin-III
Molecular Weight
52601.935 Da
References
  1. Davis R, Faulds D: Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997 Apr;10(4):299-322. [PubMed:9108990]
  2. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sialic acid binding
Specific Function
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligan...
Gene Name
SELP
Uniprot ID
P16109
Uniprot Name
P-selectin
Molecular Weight
90833.105 Da
References
  1. Simonis D, Christ K, Alban S, Bendas G: Affinity and kinetics of different heparins binding to P- and L-selectin. Semin Thromb Hemost. 2007 Jul;33(5):534-9. [PubMed:17629851]
  2. Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, Henschler R, Gille J: The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost. 2006 Mar;95(3):535-40. [PubMed:16525583]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function
Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with s...
Gene Name
FOS
Uniprot ID
P01100
Uniprot Name
Proto-oncogene c-Fos
Molecular Weight
40694.855 Da
References
  1. Nagy Z, Turcsik V, Blasko G: The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009 Dec;15(4):689-92. doi: 10.1007/s12253-009-9204-7. [PubMed:19757196]
  2. Sustar V, Jansa R, Frank M, Hagerstrand H, Krzan M, Iglic A, Kralj-Iglic V: Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin. Blood Cells Mol Dis. 2009 May-Jun;42(3):223-7. doi: 10.1016/j.bcmd.2009.01.012. Epub 2009 Mar 3. [PubMed:19261492]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.
Gene Name
MYC
Uniprot ID
P01106
Uniprot Name
Myc proto-oncogene protein
Molecular Weight
48803.55 Da
References
  1. Nagy Z, Turcsik V, Blasko G: The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009 Dec;15(4):689-92. doi: 10.1007/s12253-009-9204-7. [PubMed:19757196]
  2. Sustar V, Jansa R, Frank M, Hagerstrand H, Krzan M, Iglic A, Kralj-Iglic V: Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin. Blood Cells Mol Dis. 2009 May-Jun;42(3):223-7. doi: 10.1016/j.bcmd.2009.01.012. Epub 2009 Mar 3. [PubMed:19261492]

Drug created on June 14, 2011 23:17 / Updated on June 21, 2018 00:02